Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab by Ziping Li, Fujing Zhang, Xianghong Jin, Junling Zhuang

Subjects: Get full text

Injection site reaction to teclistamab in a patient with multiple myeloma by Isabel C. Yoon, BS, Ngan Do, MD, Thomas Vazquez, MD, David E. Elder, MD, Katherine T. Steele, MD, Misha Rosenbach, MD

Subjects: Get full text

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts by Anaïs Jiménez-Reinoso, Magdalena Molero-Abraham, Cristina Cirauqui, Belén Blanco, Eva M. Garrido-Martin, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso, Ángel Ramírez-Fernández, Laura Díez-Alonso, Ángel Nuñez-Buiza, África González-Murillo, Raquel Tobes, Eduardo Pareja, Manuel Ramírez-Orellana, José Luis Rodriguez-Peralto, Irene Ferrer, Jon Zugazagoitia, Luis Paz-Ares, Luis Álvarez-Vallina

Subjects: Get full text

Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions by Jianhua Ding, Chaihong Yeong

Subjects: Get full text

Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer by Raza Ur Rehman, MBBS, Ahmad Furqan Anjum, MBBS, Rida Fatima, MBBS

Subjects: “…Bispecific T-cell engager…”
Get full text

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach by Punchita Rujirachaivej, Teerapong Siriboonpiputtana, Kornkan Choomee, Kamonlapat Supimon, Thanich Sangsuwannukul, Pucharee Songprakhon, Krissada Natungnuy, Piriya Luangwattananun, Pornpimon Yuti, Mutita Junking, Pa-thai Yenchitsomanus

Subjects: Get full text